论文部分内容阅读
Background: This study analyzed the treatment of recurrent parotid gland cancers with radioactive iodine (125I) seed implantation.Methods: Fifteen patients with recurrent previously irradiated parotid gland cancers were treated with postoperative 125I seed implantation between April 2004 and June 2009.Local control, survival rates and side effects were retrospectively reviewed.Results:The 3-and 5-year local control rates were 67% and 53.6%, and the overall survival rates were76.2% and 66.7%, respectively.Four House-Brackman grade Ⅳ patients recovered to grade Ⅱduring follow-up.Four patients (26.7%) developed grade Ⅳ skin ulceration.Two patients (13.3%)developed moderate fibrosis of the subcutaneous tissues, and two (13.3%) suffered hearing loss for1 year after brachytherapy.There were no severe late toxicities.Conclusions: This study showed improved local control and survival rates in patients who received 125I brachytherapy.These findings should be interpreted cautiously due to the small number of patients.